Arvinas' ARV-102 Shows 50%+ LRRK2 Degradation in Parkinson’s Trial
Event summary
- Arvinas' ARV-102 achieved >50% LRRK2 degradation in CSF of Parkinson’s patients after 28 days of dosing.
- Trial showed dose-dependent brain penetration and reduction of neuroinflammatory biomarkers.
- No serious adverse events reported across all dose levels (20mg–80mg).
- Company plans Phase 1b trial in progressive supranuclear palsy (PSP) in Q2 2026.
The big picture
Arvinas’ PROTAC platform is gaining traction in neurodegenerative diseases, with ARV-102’s Phase 1 data suggesting a potential breakthrough in targeting LRRK2. The results position the company to expand into progressive supranuclear palsy (PSP), a rare but devastating tauopathy with limited treatment options. Success here could validate PROTACs as a broader therapeutic strategy for lysosomal dysfunction disorders.
What we're watching
- Clinical Progression
- Whether ARV-102 can maintain biomarker modulation in longer trials and across neurodegenerative indications.
- Regulatory Pathway
- The pace at which Arvinas advances ARV-102 toward registrational trials in Parkinson’s and PSP.
- Competitive Positioning
- How Arvinas differentiates ARV-102’s degradation approach from existing LRRK2 inhibitors.
Related topics